Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — Q3 2026 Earnings Presentation
18 slides from Niagen Bioscience's earnings presentation, Nov 4, 2026
Slide 1: Earnings Presentation Third Quarter 2026
Earnings Presentation Third Quarter 2026 Nasdaq: NAGE | November 4, 2026
Slide 2: Forward-looking statements
This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Slide 3: Executing Long-Term Strategic Growth Initiatives
Executing Long-Term Strategic Growth Initiatives Key strategic initiatives during Q3 2026. Consumer Products and Niagen Plus • Direct-to-consumer sales on the Company’s website grew by 13% year-over-year. • Launched the liquid, ready-to-inject Niagen Plus At-Home Injection Kit. • Launched Niagen Nan
Slide 4: Global authority on NAD+ and healthy aging
We are the global authority on NAD+ and healthy aging. We address aging at its root by unlocking the potential of NAD+, a vital coenzyme that declines with age. We developed Niagen®, the most efficient, high - quality NAD+ booster, and Tru Niagen®, the #1 NAD+ healthy aging supplement in the U.S. 1,
Slide 5: A Platform Built on NAD+ Science
A Platform Built on NAD+ Science NAD+ Declines by up to ~65% between the ages of 30 and 70 1 A vast body of research has established Nicotinamide Adenine Dinucleotide (NAD+) as a vital co - enzyme for cellular defense and repair NAD+ is important for energy production and is shown to help cells repa
Slide 6: World's Leading NAD+ Platform
World’s Leading NAD+ Platform INJECTABLES & TELEHEALTH CORE BUSINESS SKINCARE PHARMACEUTICAL Injectables InfusionsBranded products Ingredient partners Branded topical products and upcoming partnerships with large skincare companies Drug development for treatment of rare genetic diseases 6
Slide 7: Clinical Studies on Oral Niagen Showed Positive Outcomes
Clinical Studies on Oral Niagen ® Showed Positive Outcomes in Multiple Health Areas 2 years is the longest duration of supplementation Presterud et al., 2023 140 participants is the largest population studied in a clinical trial Conze et al., 2019 3000 mg is the highest dose with established safety
Slide 8: Scientific Advisors
Charles Brenner, Ph.D. Professor of Metabolic Regulation Faculties of Medicine, Pharmacy, and Helsinki Institute of Life Science University of Helsinki World's Foremost Authority on NAD+ Metabolism Roger Kornberg, Ph.D. Professor of Structural Biology Stanford University Nobel Prize Winner, Chemistr
Slide 9: Management Team
Andrew Shao Ph.D SVP, Global Regulatory & Scientific Affairs Nutrition scientist and regulatory expert with extensive experience in dietary supplement research, global regulatory policy, and scientific affairs. Ozan Pamir Chief Financial Officer Finance executive with deep experience in life science
Slide 10: Financial Highlights
Financial Highlights 10
Slide 11: Third Quarter 2026 Highlights
(1) See slide 15 for the non-GAAP reconciliation 62.9% gross profit margin Net loss of $(1.2) million or $(0.01) per share $0.5 million Positive Adjusted EBITDA(1) $69.5 million cash, no outstanding borrowings Third Quarter 2026 Highlights $27.2 million net sales $2.6 million Operating Cash Flow 11
Slide 12: Q3 2026: Investing for Long-Term Growth While Maintaining Financial Discipline
(1) See slide 15 for the non-GAAP reconciliation. Net Sales $27.2M Tru Niagen $23.3M Gross Margin 62.9% Net Loss $(1.2)M Adj. EBITDA(1) $0.5M Cash & Liquidity Quarter-End Cash: $69.5M Borrowings: None Strong balance sheet supports our investment in long-term growth. Q3 2026: Investing for Long-Term
Slide 13: 2025–2026 Net Sales Summary
2025 – 2026 Net Sales Summary ($ in millions) 2026 2025 Q1 Q2 Q3 Q1 Q2 Q3 Q4 FY Ecommerce 19.2 20.5 18.2 16.8 18.1 19.0 20.2 74.1 Watson’s & Other B2B 3.2 3.6 5.2 4.7 4.6 7.0 7.3 23.6 Total Tru Niagen 22.4 24.2 23.3 21.5 22.7 26.0 27.5 97.7 Food-grade Niagen 7.3 4.9 3.4 7.0 6.0 6.4 4.7 24.1 Pharmace
Slide 14: Key P&L Metrics
Three Months Ended September 30, Nine Months Ended September 30, ($ in thousands) 2026 2025 2026 2025 Net Sales 27,192 33,986 88,451 95,584 Gross Profit % of Net Sales 17,105 62.9% 21,928 64.5% 56,395 63.8% 61,485 64.3% Sales and Marketing % of Net Sales 8,713 32.0% 8,768 25.8% 28,518 32.2% 25,092 2
Slide 15: Adjusted EBITDA Summary
Adjusted EBITDA Summary Adjusted EBITDA remained positive at $0.5 million in Q3 2026 despite net loss during the quarter Reconciliation of Non-GAAP Financial Measures (In thousands) Three Months Ended FY 2025 Three Months Ended Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Net income (Loss
Slide 16: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 9/30/25 12/31/25 3/31/26 6/30/26 9/30/26 Key Drivers Since Year-End (Q4 2025 vs Q3 2026) Cash $64,290 $64,788 $66,549 $66,740 $69,509 Up $4.7 million primarily driven by positive operating results and proceeds from the sale of the non-core business,
Slide 17: Cash Flow Highlights
$2.6M operating cash flow, $69.5M cash balance and no borrowings. Cash Flow Highlights Three Months Ended FY 2025 Three Months Ended Nine Months Ended September 30, 2026 (in thousands) 3/31/25 6/30/25 9/30/25 12/31/25 3/31/26 6/30/26 9/30/26 Net Income (Loss) $5,063 $3,609 $4,578 $4,132 $17,382 $6,3
Slide 18: Contact Info
Contact Info: Niagen Bioscience Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director T: +1 (212) 896-1254 [email protected] www.niagenbioscience.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com 18